aap Implantate AG
AAQ1
ISIN DE000A3H2101 / Valor 57872565
aap Implantate AG
UMushroom community rating:
About company
aap Implantate AG, headquartered in Berlin, Germany, operates as the parent company of the aap Group, which specializes in the development, manufacturing, and distribution of medical implants. With subsidiaries including aap Implants Inc. based in Dover, Delaware, USA, MCTeQ GmbH, and MAGIC Implants GmbH, both located in Berlin, the company has established a significant presence in the medical technology sector. Additionally, aap Implantate AG holds a 4.57% stake in AEQUOS Endoprothetik GmbH. The company's portfolio primarily focuses on orthopedic implants, a field in which it aims to innovate and provide solutions that enhance patient care. Through its subsidiaries and strategic investments, aap Implantate AG leverages a combination of technological expertise and market knowledge to address the evolving needs of the healthcare industry.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.11.2025):
aap Implantate AG reported robust financial results for Q3/2025, showing a 15% year-over-year sales growth despite traditionally lower performance in this quarter. The company’s LOQTEQ® plate portfolio saw strong adoption in all markets, and an order backlog of approximately EUR 400,000 sets the stage for a promising Q4/2025. Cumulative sales for the first nine months reached EUR 9.48 million, slightly surpassing last year’s performance.
Sales Growth
In Q3/2025, aap Implantate AG achieved a 15% increase in sales compared to Q3/2024, driven largely by high demand for its innovative LOQTEQ® plate system and a solid performance even in the historically weak quarter.
Regional Performance
The company recorded varied regional growth: EMEA improved by 5%, Germany maintained modest progress with Spain/Portugal surging by approximately 30%, the US showed an 11% increase in euros (18% in local currency), LATAM grew by 21%, and APAC experienced an exceptional growth of over 200%.
Order Backlog & Future Outlook
Despite high demand resulting in temporary production and supply challenges, orders totaling around EUR 400,000 could not be delivered in Q3/2025. This backlog provides a strong foundation for Q4/2025, and the company remains confident in its forecast for 2025.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
22 M
Market cap (USD)
Daily traded volume (Shares)
1.38 / 1.29
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
